Who Exports Sunitinib from India — 114 Suppliers Behind a $63.6M Market
India's sunitinib export market is supplied by 114 active exporters who collectively shipped $63.6M across 607 shipments. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 76.2% market share, followed by DR REDDYS LABORATORIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LTD. The top 5 suppliers together control 90.1% of total export value, reflecting a concentrated market structure.
Top Sunitinib Exporters from India — Ranked by Export Value
SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading sunitinib exporter from India, holding a 76.2% share of the $63.6M market across 607 shipments from 114 exporters. The top 5 suppliers — SUN PHARMACEUTICAL INDUSTRIES LIMITED, DR REDDYS LABORATORIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LTD, MSN LABORATORIES PRIVATE LIMITED, CAPLIN POINT LABORATORIES LIMITED — collectively control 90.1% of total export value, indicating a highly concentrated market. Individual shares are: SUN PHARMACEUTICAL INDUSTRIES LIMITED (76.2%), DR REDDYS LABORATORIES LIMITED (8.2%), SUN PHARMACEUTICAL INDUSTRIES LTD (3.3%), MSN LABORATORIES PRIVATE LIMITED (1.6%), CAPLIN POINT LABORATORIES LIMITED (0.8%).
Top Sunitinib Exporters from India
Ranked by export value · 114 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED SUNITINIB MALATE CAPSULES 25MG [700 PACKX 3X10]SUNITINIB MALATE CAPSULES 25MG [737 PACKX 28 CAPSULES]SUNITINIB MALATE CAPSULES 25MG [634 PACKX 3X10] | $48.4M | 7 | 76.2% |
| 2 | DR REDDYS LABORATORIES LIMITED SUNITINIBMALATE CAPS37.5MG28'SBOTUSSUNITINIBMALATE CAPS37.5MG28'SBOTUSNEWSUNITINIB MALATE CAPS 25MG 28CRC USA PACK : 28 CAPSULE | $5.2M | 2 | 8.2% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LTD SUNITINIB MALATE CAPSULES 25MG [700 PACKX 3X10]SUNITINIB MALATE CAPSULES 25MG [737 PACKX 28 CAPSULES]SUNITINIB MALATE CAPSULES 25MG [634 PACKX 3X10] | $2.1M | 1 | 3.3% |
| 4 | MSN LABORATORIES PRIVATE LIMITED SUNITINIBMALATE CAPS37.5MG28'SBOTUSSUNITINIBMALATE CAPS37.5MG28'SBOTUSNEWSUNITINIB MALATE CAPS 25MG 28CRC USA PACK : 28 CAPSULE | $1.0M | 5 | 1.6% |
| 5 | CAPLIN POINT LABORATORIES LIMITED SUNITINIB CAPSULES 50MGSUNITINIB CAPSULES 12.5MG | $531.8K | 2 | 0.8% |
| 6 | JODAS EXPOIM PRIVATE LIMITED SUNITINIB CAPSULES 50MG NOSSUNITINIB CAPSULES 50MGSUNITINIB CAPSULES 12.5MG NOS | $428.2K | 2 | 0.7% |
| 7 | RELIANCE LIFE SCIENCES PRIVATE LIMITED | $204.8K | 2 | 0.3% |
| 8 | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED SUNITIN CAP 25MG (SUNITINIB MALATE CAPSUSUTYKA 25MG MSN -PESUTYAKA 25 MG MSN | $198.2K | 2 | 0.3% |
| 9 | TEYRO LABS PRIVATE LIMITED SUNITINIBMALATE CAPS37.5MG28'SBOTUSSUNITINIBMALATE CAPS37.5MG28'SBOTUSNEWSUNITINIB MALATE CAPS 25MG 28CRC USA PACK : 28 CAPSULE | $89.5K | 2 | 0.1% |
| 10 | EUGIA PHARMA SPECIALITIES LIMITED SUNITINIB MALATE CAPSULES 25MG [700 PACKX 3X10]SUNITINIB MALATE CAPSULES 25MG [737 PACKX 28 CAPSULES]SUNITINIB MALATE CAPSULES 25MG [634 PACKX 3X10] | $59.8K | 1 | 0.1% |
| 11 | CIPLA LIMITED SUNITINIB MALATE CAP 50MG 4X7B AU PACKSUNITINIB MALATE CAP 25MG 4X7B AU PACK | $46.0K | 1 | 0.1% |
| 12 | NV REMEDIES PRIVATE LIMITED | $27.0K | 1 | 0.0% |
| 13 | JODAS EXPOIM PVT LTD SUNITINIB CAPSULES 50MG NOSSUNITINIB CAPSULES 50MGSUNITINIB CAPSULES 12.5MG NOS | $25.8K | 2 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Sunitinib exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Warning Letter issued in | Unknown | Unknown | Unknown | FDA issued a warning letter citing CGMP violations at the Dadra facility. |
| Dr. Reddy's Laboratories Limited | Approved | Unknown | Unknown | Unknown | FDA approval for Sunitinib Malate granted on November 30, 2022. (fda.report) |
| MSN Laboratories Private Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| Caplin Point Laboratories Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| Jodas Expoim Private Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| Reliance Life Sciences Private Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| BDR Pharmaceuticals International Private Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| Teyro Labs Private Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| Eugia Pharma Specialities Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| Cipla Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| NV Remedies Private Limited | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
| Jodas Expoim Pvt Ltd | Unknown | Unknown | Unknown | Unknown | No specific FDA approvals or warning letters found. |
TransData Nexus reviewed the regulatory standing of 12 leading Sunitinib exporters from India. 1 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Sunitinib sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for pharmaceutical manufacturing, particularly for Active Pharmaceutical Ingredients (APIs). Companies like MSN Laboratories, headquartered in Hyderabad, are significant players in the production of APIs, including Sunitinib. MSN Laboratories operates multiple API and finished dosage facilities, contributing to the region's prominence in bulk drug production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Companies such as Gonane Pharma, based in Gujarat, specialize in manufacturing and marketing various pharmaceutical products, including oncology drugs like Sunitinib. Their expertise in formulations underscores the region's role as a formulations hub.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. Sun Pharmaceutical Industries Limited, headquartered in Mumbai, is India's largest pharmaceutical company and a leading exporter of Sunitinib. The region's well-developed infrastructure and proximity to major ports facilitate efficient export operations, reinforcing its status as a key export hub.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives. This region attracts numerous pharmaceutical companies seeking cost advantages, contributing to its growth as a manufacturing hub.
5Sourcing Recommendations
- Diversify Supplier Base: While Sun Pharmaceutical Industries Limited dominates Sunitinib exports, consider engaging with other manufacturers like MSN Laboratories and Gonane Pharma to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize Hyderabad's expertise in API production and Gujarat's proficiency in formulations to optimize sourcing strategies.
- Optimize Export Logistics: Capitalize on the Mumbai-Thane-Raigad region's infrastructure for efficient export operations, ensuring timely delivery to key markets like Canada and the United States.
- Explore Cost Benefits: Assess potential cost advantages by sourcing from manufacturers in the Baddi-Nalagarh region, considering the tax incentives available.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Sunitinib exporters from India
Dr. Reddy's Laboratories Limited — Dr. Reddy's sells 14 ANDAs to Senores Pharma
Dr. Reddy's Laboratories Limited divested a portfolio of 14 Abbreviated New Drug Applications (ANDAs) to Senores Pharmaceuticals. This portfolio included 13 ANDAs approved by the U.S. Food and Drug Administration (FDA) and one pending approval. - IMPACT: This divestiture may allow Dr. Reddy's to reallocate resources towards enhancing its Sunitinib production and export capabilities.
Impact: This divestiture may allow Dr. Reddy's to reallocate resources towards enhancing its Sunitinib production and export capabilities.
Common Questions — Sunitinib Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which sunitinib supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 138 recorded shipments worth $48.4M. DR REDDYS LABORATORIES LIMITED (4 shipments) and SUN PHARMACEUTICAL INDUSTRIES LTD (9 shipments) are also established high-volume exporters.
Q How many sunitinib manufacturers are there in India?
India has 114 active sunitinib exporters with a combined export market of $63.6M across 607 shipments to 76 countries. The top 5 suppliers hold 90.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for sunitinib from India?
Average FOB unit price: $164.27 per unit, ranging from $0.03 to $9957.63. Average shipment value: $104.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 114 verified Indian exporters of Sunitinib ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 607 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 76 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
607 Verified Shipments
114 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists